Release Date: July 29, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Biogen Inc BIIB reported strong revenue growth in the second quarter, with total pharmaceutical revenue reaching $1.8 billion, up 4% year over year.
- The company's growth portfolio, including SPINRAZA, LEQEMBI, and SKYCLARYS, generated over $1 billion in revenue, showing a 24% increase year over year.
- The acquisition of Apellis has strengthened Biogen Inc (BIIB)'s portfolio with SYFOVRE and EMPAVELI, contributing significantly to revenue growth.
- Biogen Inc (BIIB) has a robust late-stage pipeline with five registrational Phase 3 clinical trials expected to deliver results in the next four quarters.
- The company is actively rebuilding its early-stage pipeline, with three INDs filed this year and more expected, indicating a strong focus on long-term growth.
Negative Points
- Despite the strong performance, Biogen Inc (BIIB) faces challenges in the competitive market for SPINRAZA, with some patients switching back from oral therapies.
- The company anticipates a $0.85 non-GAAP EPS dilution in 2026 due to financing costs associated with the Apellis acquisition.
- Biogen Inc (BIIB) is experiencing increased operating expenses, with a 20% year-over-year rise in non-GAAP core OpEx, reflecting integration costs and pipeline investments.
- The market for LEQEMBI faces access challenges, with Part D coverage and prior authorization requirements potentially impacting patient uptake.
- Biogen Inc (BIIB) acknowledges the high-risk nature of its investment in Diranersen for Alzheimer's, which may not contribute to growth until the next decade.
Q & A Highlights
Q: Can you elaborate on the ramp-up of HD SPINRAZA and its impact on the franchise?
A: Alisha Alaimo, Head of North America, explained that SPINRAZA HD is exceeding expectations, with demand driven by the patient community. The product is surpassing the original SPINRAZA launch in both start forms and grads within the first 13 weeks. The majority of patients are transitioning from the lower dose to the high dose, with positive feedback from both patients and physicians. The focus for 2027 will be on new starts and switchbacks, particularly as the high dose requires fewer loading doses.
Q: What are the expectations for the lupus readouts this fall, and how do you view the differentiation of your BTK inhibitor?
A: Priya Singhal, EVP and Head of Development, expressed confidence in the trial design for the lupus studies, focusing on controlling placebo responses and patient heterogeneity. The primary endpoint is SRI-4, with key secondary endpoints including Bixler and patient-reported outcomes. Regarding the BTK inhibitor, specific doses have not been disclosed, and the company is evaluating next steps given the competitive market landscape.
Q: Can you provide insights on SYFOVRE's performance and growth expectations?
A: Alisha Alaimo highlighted that SYFOVRE had its strongest quarter since launch, with significant growth in patient numbers and prescribing physicians. The team is focusing on reducing free drug distribution and improving sentiment among healthcare providers. Future growth will be supported by a new direct-to-consumer campaign and the launch of a pre-filled syringe to enhance workflow efficiency for physicians.
Q: How do you expect the BTK inhibitor BIB091 to differentiate itself in the market, and what are your thoughts on its safety profile?
A: Priya Singhal noted that BIB091 showed compelling efficacy in RRMS, but the company is evaluating the next steps due to the competitive market. The decision to advance the asset will be based on scientific data, market opportunity, and capital allocation considerations.
Q: What feedback have you received on the CELIA data, and how might it impact your Phase 3 trial design?
A: Christopher Viehbacher stated that the CELIA data confirmed the importance of tau in cognition, with strong feedback from the medical community. The company is conducting further investigations and discussions with neurologists and the FDA, but Diranersen remains a long-term investment not expected to impact Biogen's growth this decade.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
